For instance, with a pharmacogenetics clinical trial, the researchers discovered that the response to both glipizide and metformin (glucose-lowering drugs) in individuals with the risk factors for type 2 diabetes and treatment-naive individuals with the disease has been influenced by T2D-associated TCF7L2 variants30. This evidence concerns the gene TCF7L2 and type 2 diabetes mellitus.